Profile

Biophan develops and markets cutting-edge technologies for the medical device industry. The Company's goal is to develop biomedical devices that improve the delivery of healthcare.

Committed to growth through innovation and developmental leadership, Biophan currently owns or has exclusive license to over 40 US patents, with more than 60 patent applications pending in the US or foreign countries.

Biophan has demonstrated technology leadership through the quality of its partnerships and customers. Biophan executed a license agreement with Boston Scientific Corporation in 2005, and sold some of its MRI safety patents to Medtronic for $11 million in 2007. Biophan also has a joint development agreement with the NASA Ames Center for Nanotechnology.

Biophan is traded on Pink Sheets under the symbol BIPH, and is listed on the Frankfurt Stock Exchange under the symbol BTN.

Mission Statement

Biophan is a technology development company with a strong market focus and the mission of developing novel, patent-protected technologies to provide competitive advantages to companies in the medical device market. Biophan’s current focus is continuing to develop its novel technology pipeline through grants and partnerships.